Literature DB >> 15725472

Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis.

P D Thornton1, C Bellas, A Santon, G Shah, C Pocock, A C Wotherspoon, E Matutes, D Catovsky.   

Abstract

Transformation of CLL into a large cell lymphoma has an incidence of 3-5%. We have studied 101 cases of CLL treated with fludarabine over a 10-year period (1990-2000) and observed a 12% incidence of transformation. In six of 12 patients, transformation was documented within 4 months following treatment with fludarabine. Pathological material, available in nine cases, was investigated for latent EBV by staining for LMP-1 by immunohistochemistry and EBERs-1 and 2 by in situ hybridisation. LMP-1 and EBERs were demonstrated in three of the nine samples. In two cases there was a different pattern of immunoglobulin gene rearrangement in the transformed cells assessed by PCR (FR3 fragment) compared to the original CLL clone. One of these two cases showed evidence of latent EBV. The other seven cases, of which two were EBV positive, showed identical pattern of Ig gene rearrangement in both the CLL and the transformed cells. We suggest that the relatively high incidence of transformation in this series may be due to immunosuppression mainly related to fludarabine, although other agents and prior therapies may have also contributed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15725472     DOI: 10.1016/j.leukres.2004.09.008

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  16 in total

Review 1.  Recent advances in the diagnosis and therapy of Richter's syndrome.

Authors:  Ronan Swords; John Bruzzi; Francis Giles
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

2.  Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor?

Authors:  Riccardo Dolcetti; Antonino Carbone
Journal:  Infect Agent Cancer       Date:  2010-11-22       Impact factor: 2.965

3.  Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia.

Authors:  A Hayat; S McGuckin; E Conneally; P V Brown; S R McCann; M Lawler; F Quinn; E Delaney; P O'Rourke; S Liptrot; D O'Brien; E Vandenberghe
Journal:  Ir J Med Sci       Date:  2009-12       Impact factor: 1.568

4.  Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS).

Authors:  Nina D Wagner-Johnston; Brian K Link; Michelle Byrtek; Keith L Dawson; John Hainsworth; Christopher R Flowers; Jonathan W Friedberg; Nancy L Bartlett
Journal:  Blood       Date:  2015-06-23       Impact factor: 22.113

5.  How we treat Richter syndrome.

Authors:  Sameer A Parikh; Neil E Kay; Tait D Shanafelt
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113

6.  The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011).

Authors:  Melhem Solh; Kanti R Rai; Bercedis L Peterson; Jonathan E Kolitz; Frederick R Appelbaum; Martin S Tallman; Andrew Belch; Richard A Larson; Vicki A Morrison
Journal:  Leuk Lymphoma       Date:  2012-09-08

7.  Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France.

Authors:  Leticia Quintanilla-Martinez; Daphne de Jong; Antoine de Mascarel; Eric D Hsi; Philip Kluin; Yaso Natkunam; Marie Parrens; Stefano Pileri; German Ott
Journal:  J Hematop       Date:  2009-12-22       Impact factor: 0.196

8.  Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion.

Authors:  Wenbin Xiao; Wayne W Chen; Lynn Sorbara; Theresa Davies-Hill; Stefania Pittaluga; Mark Raffeld; Elaine S Jaffe
Journal:  Hum Pathol       Date:  2016-05-14       Impact factor: 3.466

9.  Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.

Authors:  Brian K Link; Matthew J Maurer; Grzegorz S Nowakowski; Stephen M Ansell; William R Macon; Sergei I Syrbu; Susan L Slager; Carrie A Thompson; David J Inwards; Patrick B Johnston; Joseph P Colgan; Thomas E Witzig; Thomas M Habermann; James R Cerhan
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

10.  Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia.

Authors:  Ann Janssens; Marc Boogaerts; Gregor Verhoef
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.